{"id":14896,"date":"2019-02-14T04:03:59","date_gmt":"2019-02-14T04:03:59","guid":{"rendered":"http:\/\/faceinews.com\/?p=14896"},"modified":"2019-02-14T04:03:59","modified_gmt":"2019-02-14T04:03:59","slug":"dr-agarwal-group-of-eye-hospitals-raises-rs-270-crore-funding-from-temasek","status":"publish","type":"post","link":"https:\/\/www.faceinews.com\/?p=14896","title":{"rendered":"Dr. Agarwal Group of Eye Hospitals Raises Rs. 270 Crore Funding from Temasek"},"content":{"rendered":"

\"DSC_2849\"<\/a><\/p>\n

\"Faceinews<\/a><\/p>\n

Chennai,\u00a0 February 2019: Dr. Agarwal\u2019s Healthcare Ltd. (DAHCL) has raised Rs. 270 crore investment from Temasek, a global investment company headquartered in Singapore. The investment will be used to expand the Indian geographical footprint of the international eye care chain, along with significant investments in latest technology for super specialty eye-care.<\/p>\n

Temasek is a global investor anchored in Asia, with India accounting for around 4% of its S$308<\/span> billion (US$235b) portfolio as at 31 March 2018. Temasek\u2018s healthcare portfolio in India includes investments in Medanta MediCity, Manipal Hospitals and HealthCare Global.<\/p>\n

\u201cThe Agarwal Group is excited to welcome Temasek as an investor. We believe their expertise and support will help our company expand our network of clinics and operations to better meet the growing demand for affordable and quality eye care across India.\u201d said Prof. (Dr.) Amar Agarwal, (MS, FRCS, FRC Ophth), Chairman, Dr. Agarwal\u2019s Group of Eye Hospitals.<\/p>\n

Dr. Adil Agarwal, CEO, Dr. Agarwal\u2019s Group of Eye Hospitals said that \u201cWe are looking at adding anywhere between 50-75 hospitals to our network over the next 3-5 years with a major focus on metro cities as well as tier 2 and tier 3 towns. The expansion will be done through a mix of strategic partnerships, acquisitions and greenfield hospitals. Innovation and technology will continue to be at the forefront of our growth, and we will be investing more in cutting edge technology such as SMILE, FemtoLaser and Robotic Cataract Surgery across our centers. Our aim is to deliver high quality eye care at affordable prices at people\u2019s doorsteps\u201d.<\/p>\n

Veda Corporate Advisors, a leading mid-market investment bank advised the Company on the transaction. Veda also advised the Company on its previous round of investment from ADV Partners.<\/p>\n

The Dr Agarwal Eye Hospital group has been at the forefront of innovation in the field of Ophthalmology with procedures such as Glued IOL (to treat patients with complicated lens problems), PDEK (an ultra-modern form of Corneal transplants) and PhakoNIT (Removal of Cataract through a sub 1mm incision). The latest invention from the group is a novel technique called \u201cSingle-Pass Four Throw\u201d (SFT) along with \u201cPin Hole Pupilloplasty\u201d, which is also referred to as PPP. The surgical technique is being used to help in pupillary reconstruction as well as to treat complicated cases of Narrow Angle Glaucoma.\u00a0 There is also a lot of focus on education and training and the group attracts doctors from across the globe for its training programs; They also offer a DNB (post graduate) program and various fellowship programs to train young, budding surgeons.<\/p>\n

\u201cADV welcomes Temasek as a new partner in Dr Agarwal\u2019s growth story; this investment will further strengthen the company\u2019s leadership position in India\u2019s eye-care ecosystem\u201d said Mr. Suresh Prabhala, Co-founder, ADV Partners. ADV Partners invested Rs 270 crores in Dr Agarwal\u2019s HealthCare Ltd in 2016 and has been a key component of the company\u2019s board and growth story.<\/p>\n","protected":false},"excerpt":{"rendered":"

Chennai,\u00a0 February 2019: Dr. Agarwal\u2019s Healthcare Ltd. (DAHCL) has raised Rs. 270 crore investment from Temasek, a global investment company headquartered in Singapore. The investment will be used to expand the Indian geographical footprint of the international eye care chain, along with significant investments in latest technology for super specialty eye-care. Temasek is a global […]<\/p>\n","protected":false},"author":2,"featured_media":14897,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31],"tags":[],"class_list":["post-14896","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"_links":{"self":[{"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/posts\/14896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14896"}],"version-history":[{"count":1,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/posts\/14896\/revisions"}],"predecessor-version":[{"id":14898,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/posts\/14896\/revisions\/14898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/media\/14897"}],"wp:attachment":[{"href":"https:\/\/www.faceinews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}